Premium
Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience
Author(s) -
Unal Sule,
Fidan Gulin,
Tavil Betul,
Çetin Mualla,
Çetinkaya Duygu Uçkan
Publication year - 2007
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2007.00727.x
Subject(s) - medicine , chronic myelogenous leukemia , hematopoietic stem cell transplantation , imatinib mesylate , transplantation , leukemia , stem cell , oncology , bone marrow transplantation , imatinib , immunology , myeloid leukemia , biology , genetics
Recently, there are emerging reports on the beneficial effect of imatinib mesylate for pediatric CML patients; however, the general recommendation is that high‐risk CML patients with a human leukocyte antigen‐identical donor should be transplanted within the first 12 months after diagnosis. Herein, the data of 16 allogeneic HSCT in 14 children with CML were analyzed retrospectively. In the present study, three‐yr EFS was 54.1 ± 10.8% and three‐yr OS was found as 80.7 ± 12.5%.